Plan B advocates plotting response to FDA delay in OTC approval

Advocates of the "morning after" emergency contraceptive drug are planning a reaction strategy to the FDA's delay of a decision on over-the-counter status for the drug despite an advisory panel's recommendation in December for OTC status. Saying it needed more time to review data, the agency put off a decision, prompting women's and public-health groups to accuse it of yielding to pressure from anti-contraception groups. Meanwhile, the Virginia House of Delegates took a preliminary step in voting to restrict the dispensing of such drugs.

View Full Article in:

Washington Post (tiered subscription model), The · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations